China biotech taps Big Data as next weapon against cancer
Entrepreneurs and scientists are also aiming to dominate the market for complex new procedures
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Hong Kong
WHEN Nisa Leung was pregnant with her first child in 2012, her doctor in Hong Kong offered her a choice. She could take a prenatal test that would require inserting a needle into her uterus, or pay US$130 more for an exam that would draw a little blood from her arm.
Ms Leung opted for the simpler and less risky test, which analysed bits of the baby's DNA that had made its way into her bloodstream. Then, Ms Leung went on to do what she often does when she recognises a good product: look around for companies to invest in.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
